Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sihuan Granted SFDA Approval to Test New Diabetes Drug

publication date: Feb 22, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sihuan Pharma received permission from the SFDA to begin clinical trials of pinoxacin hydrochloride, a Category 1.1 drug. The drug is a DPP-4 inhibitor that is intended for type 2 diabetics. The Beijing-based company said it would start a Phase I trial in the first half of 2013. In January, Sihuan announced approval to begin clinical trials of another Category 1.1 drug, an innovative carbapenem antibiotic known as benapenum. So far, four of Sihuan’s Category 1 drugs have received approval for human testing. More details....

Stock Symbol: (HK: 0460)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners